ASAP supports three programs and serves as a member of multiple consortia to advance research for the benefit of the global Parkinson’s disease community.
ASAP shares the impact that our initiative, network, and supported programs have had on providing new insights into Parkinson’s disease. Discover news, interviews, awards, and annual impact.
ASAP is dedicated to facilitating a research environment where meaningful collaboration, research-enabling resources, and data sharing provides the answers we need to understand, diagnose, and treat Parkinson’s disease. Discover our open science philosophy.
ASAP is committed to developing and openly sharing research outputs, including data, code, protocols, and key lab materials, to help the scientific community build upon existing work.
LID is poorly understood, our research on dyskinetic mice show SPNs' properties oscillate during LID and are influenced by dopamine and acetylcholine signaling. Targeting M1 receptors in iSPNs reduced LID severity and improved levodopa effects.
CRISPR-SaCas9 for in vivo genome editing. Used to locate and cleave specific double-stranded DNA sequences.
Guide RNA (CRISPR-saCas9) for GABRD and GABRA4
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
